These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 29272392

  • 41. SEN Virus infection in HIV/HCV coinfected patients.
    Sagir A, Adams O, Oette M, Vogel M, Kupfer B, Emmelkamp J, Rockstroh J, Häussinger D.
    Eur J Med Res; 2008 Nov 24; 13(11):495-9. PubMed ID: 19073384
    [Abstract] [Full Text] [Related]

  • 42. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Nov 24; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.
    Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.
    J Immunol; 2019 Aug 01; 203(3):705-717. PubMed ID: 31253727
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Effect of HCV viral dynamics on treatment design: lessons learned from HIV.
    Bain VG.
    Am J Gastroenterol; 2001 Oct 01; 96(10):2818-28. PubMed ID: 11693314
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.
    J Viral Hepat; 2014 Mar 01; 21(3):178-88. PubMed ID: 24438679
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia.
    Zhang RF, Sun HQ, Huang Q, Wang JR, Zhang XX, Liu XN, Ma Q, Lu HZ.
    Haemophilia; 2010 May 01; 16(3):502-7. PubMed ID: 20028427
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R, Vigano S, Rasmussen TA, Søgaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Østergaard L, Tolstrup M, Lichterfeld M.
    J Virol; 2015 Oct 01; 89(20):10176-89. PubMed ID: 26223643
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
    Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, Ruiz-Valderas R, Jimenez L, Arizcorreta A, Terrón A, Viciana P.
    Clin Pharmacol Ther; 2008 Nov 01; 84(5):573-80. PubMed ID: 18596682
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
    Monje-Agudo P, Castro-Iglesias A, Rivero-Juárez A, Martínez-Marcos F, Ortega-González E, Real LM, Pernas B, Merchante N, Cid P, Macías J, Merino MD, Rivero A, Mena A, Neukam K, Pineda JA, Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica.
    Eur J Clin Microbiol Infect Dis; 2015 Oct 01; 34(10):1929-36. PubMed ID: 26155784
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
    Rivero-Juarez A, Lopez-Cortes LF, Camacho A, Caruz A, Torres-Cornejo A, Martinez-Dueñas L, Ruiz-Valderas R, Torre-Cisneros J, Gutierrez-Valencia A, Rivero A.
    AIDS; 2013 Jul 31; 27(12):1941-7. PubMed ID: 23917425
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.